18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer

2003 ◽  
Vol 42 (04) ◽  
pp. 145-156 ◽  
Author(s):  
W. Weber ◽  
M. Schwaiger ◽  
H. Schicha ◽  
M. Dietlein
Keyword(s):  
Colorectal Cancer ◽  
Fdg Pet ◽  
Classification Systems ◽  
Correct Selection ◽  
Daily Routine ◽  
Health Administration ◽  
Clinical Implementation ◽  
Level Of Evidence ◽  
Selection Of Patients ◽  
Selection Of

Summary: Aim, method: Recommendations for the use of FDG-PET in relapsed colorectal cancer and the decision of reimbursement should base on published studies and on their level of evidence. Therefore, the PET-studies published between 1997 and 2002 were graded by the bias-criteria, by two rating-systems and by two classification-systems for the level of evidence according to AHCPR (Agency for Health Care Policy and Research) and VHA (Veterans Health Administration). Results: The recommendation for the use of PET in relapsed colorectal cancer reached the level IIa according to the AHCPR, corresponding to level B according to the VHA. The sensitivity and specificity of FDG-PET were 94% (95% CI: 91-96%) and 78% (95% CI: 69-86%), respectively. Staging was changed correctly in 27% of patients (95% CI: 24-30%). Staging by FDG-PET was incorrect in 4% of the patients (95% CI: 2-5%) compared with the conventionel methods. The additional use of PET changed the prospectively defined management plan for 34% of patients (95% CI: 31-38%). Either potentially curative operations were initiated in case of resectable tumour or futile operations were cancelled in case of multiple metastases. Conclusion: The 3-year-survival-rate following surgery would have exceeded 70% if the selection of patients had included an additional PET-examination. The correct selection of patients is requested in the daily routine as well as in the clinical implementation of neoadjuvant therapies to prevent a selection-bias from a suboptimal restaging without PET.

FDG-PET improves the staging and selection of patients with recurrent colorectal cancer

2002 ◽  
Vol 29 (7) ◽  
pp. 915-921 ◽  
Author(s):  
Max Lonneux ◽  
Abdel-Malek Reffad ◽  
Roger Detry ◽  
Alex Kartheuser ◽  
Jean-François Gigot ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Fdg Pet ◽  
Recurrent Colorectal Cancer ◽  
Selection Of Patients ◽  
Selection Of

scholarly journals Bevacizumab in neoadjuvant treatment of patients with liver metastases from colorectal carcinoma

2010 ◽  
Vol 18 (3) ◽  
pp. 75-78
Author(s):  
Ivan Nikolic ◽  
Svetlana Pavin ◽  
Biljana Kukic ◽  
Bogdan Bogdanovic ◽  
Miroslav Ilic ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Neoadjuvant Treatment ◽  
Hepatic Metastases ◽  
Response Rates ◽  
Control Group ◽  
Significant Difference ◽  
Experimental Group ◽  
Selection Of Patients ◽  
Selection Of

Background: Liver metastases are the leading cause of death in patients with colorectal cancer. Despite advances in chemotherapy, surgical resection of hepatic metastases is still considered the only curative options. However, the majority of patients have inoperable disease at presentation. Perioperative chemotherapy is the most successful way for improved selection of patients for resection. The aim of the study was to demonstrate if and to what extent does bevacizumab, introduced in chemotherapy, increase response rates, and development of liver metastases. Methods: Our study included 50 patients who were divided in two groups. The experimental group included patients who were treated with bevacizumab plus chemotherapy, and the control group included patients who were treated with chemotherapy only. Results: The comparison showed that the patients who were treated with bevacizumab became candidates for resection of liver metastases in higher percentage (85%:52%). In addition, distribution of patients regarding the development of metastases resulted in statistically significant difference. Ratio between the patients with good response from the experimental and the control group was 67%:39%. Ratio of patients with stable disease was 26%:48%, and of patients with progressive disease, it was 7%:3%. The estimate of margin after resection was statistically insignificant. Conclusion: Bevacizumab in combination with chemotherapy in therapy of liver metastases from primary colorectal cancer improves and increases response rates and development of liver metastases.

scholarly journals Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2001 ◽  
Author(s):  
Reetu Mukherji ◽  
John Marshall ◽  
Andreas Seeber
Keyword(s):  
Colorectal Cancer ◽  
Current Knowledge ◽  
Locally Advanced ◽  
Tumor Resection ◽  
Daily Routine ◽  
Precision Oncology ◽  
Genomic Alterations ◽  
Future Challenges ◽  
The Status ◽  
Selection Of

The selection of treatment according to genomic alterations is a standard approach in metastatic colorectal cancer but is only starting to have an impact in the earlier stages of the disease. The status of genes like KRAS, BRAF, and MMR has substantial survival implications, and concerted research efforts have revolutionized treatment towards precision oncology. In contrast, a genomic-based approach has not changed the adjuvant setting after curative tumor-resection in the daily routine so far. This review focuses on the current knowledge regarding prognostic and predictive genomic biomarkers in patients with locally advanced nonmetastasized colorectal cancer. Furthermore, we provide an outlook on future challenges for a personalized adjuvant treatment approach in patients with colorectal cancer.

scholarly journals Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy inKRASWild-Type Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Tze-Kiong Er ◽  
Chih-Chieh Chen ◽  
Luis Bujanda ◽  
Marta Herreros-Villanueva
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor Receptor ◽  
Predictive Biomarkers ◽  
Genetic Determinants ◽  
Secondary Resistance ◽  
Epidermal Growth ◽  
The Right ◽  
Colorectal Cancer Patients ◽  
Selection Of Patients ◽  
Selection Of

Targeting epidermal growth factor receptor (EGFR) has been one of the most effective colorectal cancer strategies. Anti-EGFR antibodies function by binding to the extracellular domain of EGFR, preventing its activation, and ultimately providing clinical benefit.KRASmutations in codons 12 and 13 are recognized prognostic and predictive biomarkers that should be analyzed at the clinic prior to the administration of anti-EGFR therapy. However, still an important fraction ofKRASwild-type patients do not respond to the treatment. The identification of additional genetic determinants of primary or secondary resistance to EGFR targeted therapy for further improving the selection of patients is urgent. Herein, we review the latest published literature highlighting the most important genes that may predict resistance to anti-EGFR monoclonal antibodies in colorectal cancer patients. According to the available findings, the evaluation ofBRAF,NRAS,PIK3CA, andPTENstatus could be the right strategy to select patients who are likely to respond to anti-EGFR therapies. In the future, the combination of those biomarkers will help establish consensus that can be introduced into clinical practice.

MAGNETIC LASER THERAPY OF IRRITATIVE URINARY DISORDERS AFTER SURGICAL TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Vestnik ◽  
2021 ◽  
pp. 166-168
Author(s):  
А.М. Жаксыбергенов ◽  
А.А. Марат ◽  
Ф.Ж. Хатамов ◽  
Ж.К. Нарманов ◽  
Ж.К. Сырлыбек
Keyword(s):  
Surgical Treatment ◽  
Benign Prostatic Hyperplasia ◽  
Laser Therapy ◽  
Prostate Gland ◽  
Prostatic Hyperplasia ◽  
Correct Selection ◽  
Urinary Disorders ◽  
Magnetic Laser Therapy ◽  
Selection Of Patients ◽  
Selection Of

Цель: Несмотря на четко определенные критерии отбора пациентов для лечения доброкачественная гиперплазия предстательной железы (ДГПЖ), часть больных остается неудовлетворенной результатами операции. Это вынуждает искать дополнительные методы лечения, которые могли бы войти в комплекс реабилитационных мероприятий для этой категории больных. Методы: В настоящем исследовании мы проанализировали группу пациентов из 69 больных, перенесших оперативное лечение по поводу ДГПЖ (как трансуретральную резекцию предстательной железы, так и открытую аденомэктомию), имевших в послеоперационном периоде выраженную ирритативную симптоматику. Результаты: Эффекты магнитно-лазерной терапии в зоне оперированной предстательной железы способны воздействовать на те звенья патогенеза ирритативных расстройств мочеиспускания, которые недоступны другим методам. Выводы: При правильном отборе пациентов применение магнитно-лазерной терапии на зону оперированной железы, задней уретры и мочевого пузыря позволяет достичь удовлетворяющего пациента результата операции в гораздо ранние сроки, нередко существенно сократить послеоперационной койко-день, в ряде случаев избежать длительного курса антибактериальной терапии или дорогостоящих α--адреноблокаторов. Purpose: Despite the clarity of the selection of patients for the treatment of benign prostatic hyperplasia (BPH), some of the patients are unsatisfied with the results of the operation. This forces us to look for additional methods of treatment that could be included in the complex of rehabilitation measures for this category of patients. Methods: In this study, we analyzed a group of patients from 69 patients who underwent surgical treatment for BPH (both transurethral resection of the prostate gland and open adenomectomy) who had severe irritative symptoms in the postoperative period. Results: The effects of magnetic laser therapy in the area of the operated prostate can affect those links in the pathogenesis of irritative urinary disorders that are inaccessible to other methods. Conclusions: With the correct selection of patients, the use of magnetic laser therapy on the area of the operated gland, posterior urethra and bladder allows achieving a satisfactory surgical result at a much earlier time, often significantly shortening the postoperative bed-day, in some cases avoiding a long course of antibiotic therapy or expensive α-adrenergic blockers.

Paroxysmal hemoglobinuria

1930 ◽  
Vol 26 (10) ◽  
pp. 969-972
Author(s):  
G. A. Nagibin
Keyword(s):  
Correct Selection ◽  
Clinical Form ◽  
Selection Of Patients ◽  
Selection Of

This rare clinical form deserves to be noted not only as a casuistic material, but also because the patient with this form was sent by the TB dispensary to the sanatorium as a tuberculosis one, after 6 months of observation, with a diagnosis of B-II fibro-productive. All the material of the sanatorium is now being developed in terms of the correct selection of patients.

scholarly journals Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1990
Author(s):  
Romain Cohen ◽  
Qian Shi ◽  
Thierry André
Keyword(s):  
Colorectal Cancer ◽  
Checkpoint Inhibitors ◽  
Early Stage ◽  
Disease Recurrence ◽  
Prognostic Features ◽  
T Cell Infiltration ◽  
Tumor Mutational Burden ◽  
Patients At Risk ◽  
Selection Of Patients ◽  
Selection Of

Immune checkpoint inhibitors (ICI) have reshaped therapeutic strategies for cancer patients. The development of ICI for early stage colorectal cancer is accompanied by specific challenges: (i) the selection of patients who are likely to benefit from these treatments, i.e., patients with tumors harboring predictive factors of efficacy of ICI, such as microsatellite instability and/or mismatch repair deficiency (MSI/dMMR), or other potential parameters (increased T cell infiltration using Immunoscore® or others, high tumor mutational burden, POLE mutation), (ii) the selection of patients at risk of disease recurrence (poor prognostic features), and (iii) the choice of an accurate clinical trial methodological framework. In this review, we will discuss the ins and outs of clinical research of ICI for early stage MSI/dMMR CC patients in adjuvant and neoadjuvant settings. We will then summarize data that might support the development of ICI in localized colorectal cancer beyond MSI/dMMR.

Sign in / Sign up

Export Citation Format

Share Document